Aurobindo Pharma Q1 Result: Profit Rises, In Line With Estimates
The Hyderabad-based bulk and generic drug maker's net profit jumped 61% year-on-year to Rs 918 crore in the quarter ended June 30, 2024.
.webp?rect=0%2C21%2C509%2C286&w=200)
Aurobindo Pharma Ltd.'s first-quarter profit increased, meeting analysts' estimates.
The Hyderabad-based bulk and generic drug maker's net profit jumped 61% year-on-year to Rs 918 crore in the quarter ended June 30, 2024, according to an exchange filing. That compares with the Rs 941-crore consensus estimate of analysts tracked by Bloomberg.
Aurobindo Pharma Q1 FY25 Result Highlights (Year-on-Year)
Revenue up 10% at Rs 7,567 crore vs Rs 6,851 crore (Bloomberg estimate: Rs 7,580 crore).
Ebitda up 40% at Rs 1,619 crore vs Rs 1,153 crore (Bloomberg estimate: Rs 1,617 crore).
Ebitda margin at 21.4% vs 16.8% (Bloomberg estimate: 21.30%).
Net profit up 61% at Rs 918 crore vs Rs 570 crore (Bloomberg estimate: Rs 941 crore).
Key Highlights
Revenue from operations increased by 10.5% year-on-year to Rs 7,567 crore with growth across the businesses.
US formulations, excluding Puerto Rico (its wholly owned subsidiary), revenue increased by 13.3% year on year to Rs 3,555 crore ($426 million).
Europe formulations revenue increased by 7.9% year on year to Rs 1,982 crore (221 million euros).
Growth markets revenue increased by 49.2% year on year to Rs 709 crore ($85 million).
Antiretroviral revenue increased by 13.9% year on year to Rs 229 crore ($27 million).
API revenue grew by 5.6% year on year to Rs 1,092 crore ($131 million).
Research and development spend was Rs 339 crore, 4.5% of revenues.
Shares of Aurobindo Pharma closed 2.52% lower on Friday a day before the results were announced, compared to a 1.04% rise in the benchmark Nifty.
